Patents by Inventor Jui DUTTA-SIMMONS
Jui DUTTA-SIMMONS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240352151Abstract: Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7. Also provided herein are genetically engineered T cells expressing a masked CAR specific to PTK7 and therapeutic uses thereof.Type: ApplicationFiled: March 4, 2024Publication date: October 24, 2024Inventors: Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
-
Patent number: 11926676Abstract: Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7. Also provided herein are genetically engineered T cells expressing a masked CAR specific to PTK7 and therapeutic uses thereof.Type: GrantFiled: May 6, 2021Date of Patent: March 12, 2024Assignee: CRISPR THERAPEUTICS AGInventors: Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
-
Patent number: 11919970Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: GrantFiled: December 14, 2020Date of Patent: March 5, 2024Assignee: Juno Therapeutics, Inc.Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
-
Publication number: 20240018256Abstract: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: ApplicationFiled: July 5, 2023Publication date: January 18, 2024Applicant: Juno Therapeutics, Inc.Inventors: Yan CHEN, Steven M. Shamah, Csaba Pazmany, Jui DUTTA-SIMMONS
-
Patent number: 11827714Abstract: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: GrantFiled: December 2, 2019Date of Patent: November 28, 2023Assignee: Juno Therapeutics, Inc.Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
-
Publication number: 20230365699Abstract: Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-BCMA antibodies or antigen-binding fragments thereof specifically bind to BCMA-1. Among the anti-BCMA antibodies are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs or BCMA-binding molecules and uses thereof such as in adoptive cell therapy.Type: ApplicationFiled: April 7, 2023Publication date: November 16, 2023Applicant: Juno Therapeutics, Inc.Inventors: Blythe D. SATHER, Steven M. SHAMAH, Yan CHEN, Rebecca WU, Collin HAUSKINS, Csaba PAZMANY, Jui DUTTA-SIMMONS, Kimberly HARRINGTON
-
Publication number: 20230181750Abstract: Mask peptides for use in producing masked antibodies specific to tyrosine-protein kinase-like 7 (PTK7). Also provided herein are masked anti-PTK7 antibodies comprising the mask peptide and therapeutic uses thereof.Type: ApplicationFiled: May 6, 2021Publication date: June 15, 2023Inventors: Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
-
Patent number: 11623961Abstract: Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-BCMA antibodies or antigen-binding fragments thereof specifically bind to BCMA-1. Among the anti-BCMA antibodies are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs or BCMA-binding molecules and uses thereof such as in adoptive cell therapy.Type: GrantFiled: November 1, 2018Date of Patent: April 11, 2023Assignee: Juno Therapeutics, Inc.Inventors: Blythe D. Sather, Steven M. Shamah, Yan Chen, Rebecca Wu, Collin Hauskins, Csaba Pazmany, Jui Dutta-Simmons, Kimberly Harrington
-
Publication number: 20210347913Abstract: Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7. Also provided herein are genetically engineered T cells expressing a masked CAR specific to PTK7 and therapeutic uses thereof.Type: ApplicationFiled: May 6, 2021Publication date: November 11, 2021Inventors: Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
-
Publication number: 20210324100Abstract: Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.Type: ApplicationFiled: June 21, 2021Publication date: October 21, 2021Applicants: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer CenterInventors: Blythe D. SATHER, Eric L. SMITH, Rupesh AMIN, Aye CHEN, Kimberly HARRINGTON, Collin HAUSKINS, Erik HESS, Cyr DE IMUS, Jon JONES, Audrey OLSHEFSKY, Stefan PONKO, Ruth SALMON, Semih TAREEN, Rebecca WU, Yan CHEN, Steven M. SHAMAH, Csaba PAZMANY, Jui DUTTA-SIMMONS, Mariana Cota STIRNER, Melissa WORKS
-
Publication number: 20210238309Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: ApplicationFiled: December 14, 2020Publication date: August 5, 2021Applicant: Juno Therapeutics, Inc.Inventors: Yan CHEN, Steven M. SHAMAH, Csaba PAZMANY, Jui DUTTA-SIMMONS
-
Patent number: 11066475Abstract: Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.Type: GrantFiled: November 1, 2018Date of Patent: July 20, 2021Assignees: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer CenterInventors: Blythe D. Sather, Eric L. Smith, Rupesh Amin, Aye Chen, Kimberly Harrington, Collin Hauskins, Erik Hess, Cyr De Imus, Jon Jones, Audrey Olshefsky, Stefan Ponko, Ruth Salmon, Semih Tareen, Rebecca Wu, Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons, Mariana Cota Stirner, Melissa Works
-
Patent number: 10889652Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: GrantFiled: June 4, 2018Date of Patent: January 12, 2021Assignee: Juno Therapeutics, Inc.Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
-
Publication number: 20200392236Abstract: Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-BCMA antibodies or antigen-binding fragments thereof specifically bind to BCMA-1. Among the anti-BCMA antibodies are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs or BCMA-binding molecules and uses thereof such as in adoptive cell therapy.Type: ApplicationFiled: November 1, 2018Publication date: December 17, 2020Applicant: Juno Therapeutics, Inc.Inventors: Blythe D. SATHER, Steven M. SHAMAH, Yan CHEN, Rebecca WU, Collin HAUSKINS, Csaba PAZMANY, Jui DUTTA-SIMMONS, Kimberly HARRINGTON
-
Publication number: 20200172630Abstract: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: ApplicationFiled: December 2, 2019Publication date: June 4, 2020Applicant: Juno Therapeutics, Inc.Inventors: Yan CHEN, Steven M. SHAMAH, Csaba PAZMANY, Jui DUTTA-SIMMONS
-
Patent number: 10533055Abstract: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: GrantFiled: August 28, 2015Date of Patent: January 14, 2020Assignee: JUNO THERAPEUTICS, INC.Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
-
Publication number: 20180265593Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: ApplicationFiled: June 4, 2018Publication date: September 20, 2018Applicant: Juno Therapeutics, Inc.Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
-
Publication number: 20160152723Abstract: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: ApplicationFiled: August 28, 2015Publication date: June 2, 2016Applicant: JUNO THERAPEUTICS, INC.Inventors: Yan CHEN, Steve SHAMAH, Csaba PAZMANY, Jui DUTTA-SIMMONS